Introduction
The 2008 World Health Organization (WHO) classification of tumors of hematopoietic and lymphoid tissues has recognized a new provisional entity designated as Epstein-Barr viruspositive diffuse large B-cell lymphoma (DLBCL) of the elderly. This tumor is defined as an EBV-positive monoclonal large B-cell lymphoproliferative disorder arising in immunocompetent patients > 50 years. 1 To denote patient age in the definition was a means of emphasizing the tendency of these tumors to arise in patients of advanced age, but this age cutoff is clearly arbitrary, and EBV-positive DLBCL of the elderly has been reported rarely in younger patients.
Since the initial description of 22 patients with EBV-positive DLBCL of the elderly in 2003
by Oyama et al, 2 knowledge of EBV-mediated mechanisms of oncogenesis, microRNA profiles in EBV-positive lymphomas and novel efficient therapeutics for patients with these neoplasms have been developed. In this review, we discuss the epidemiology, clinicopathologic features, and differential diagnoses of EBV-positive DLBCL of the elderly.
We also review novel molecular findings including host and virus-induced miRNAs, and some novel therapeutic approaches.
Epidemiology
The median age of patients with EBV-positive DLBCL of the elderly is 71 years (range, 50-91), however, younger patients can be affected. 3 There is a slight male predominance with a male to female ratio of 1.4 to 1. [4] [5] [6] [7] [8] [9] [10] There is a higher prevalence of EBV-positive DLBCL among East Asians (8.7-11.4%) [11] [12] [13] compared with less than 5% in Western countries 5, 6 ( Table 1) . Meanwhile, Beltran et al 4 has reported the highest frequency of EBV-positive DLBCL in a Peruvian population, 14.9%, using a criterion of ≥
20% cells with positive EBV-
For personal use only. on November 1, 2017 . by guest www.bloodjournal.org From encoded RNA (EBER) expression. Of note, there are no uniform criteria for the percentage of EBV-positive cells in EBV-positive DLBCL and this is a limitation when assessing disease prevalence. The fact that differences in cutoffs for EBER positivity clearly impact the frequency of EBV positive DLBCL was respectively shown by Wada et al and others. [13] [14] [15] These authors emphasize the need for establishing uniform criteria for EBV positivity, either >20%, >50%, or almost all tumor cells. Hofscheier et al interpreted EBER-positive DLBCL with <20% EBER as clonally unrelated EBV-transformed B-cells or secondary EBV infection in an established B-cell clone. 7 The definitive criterion for EBV positivity in EBV-positive DLBCL is remained to be agreed.
Epidemiologic features correlate with geographical differences in the literature. In contrast with East Asian series, cases in Mexico display a relatively younger age at presentation, with predominantly nodal disease and rare expression of the EBNA2. 7 Recent evidence casts a doubt on geographic and/or ethnic variation in the prevalence of EBV-positive DLBCL of the elderly. Contrary to earlier reports from the Far East, a report from Northern China showed a frequency of EBV positivity in only 8 of 212 (3.8%) in patients >50 years old with DLBCL (using a cutoff of >50% EBER positivity).
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Pathogenetic aspects
From an immunologic viewpoint, aging can be characterized as a dysregulated relationship between inflammatory and inflammation-neutralizing processes, resulting in a low-grade chronic pro-inflammatory state. 16 This imbalance might exert other potential effects promoting lymphomagenesis. Inflammation induces radical oxygen species which can cause dysregulation of critical oncogenic pathways, such as p53, retinoblastoma (Rb), NF-κB, and mitogen-activated protein (MAP) kinases. 17 For personal use only. on November 1, 2017 . by guest www.bloodjournal.org From It has been postulated that EBV-positive DLBCL of the elderly might be caused by the senescence of the immune system, as a part of the normal aging process, based largely on shared features with immunodeficiency-associated lymphoproliferative disorders (LPDs).
These shared features include EBV infection, similar EBV latency pattern, morphologic similarities, and presence of monoclonal T-cell populations. 8, 12, 18, 19 Of note, immunosenescence is not simply the result of a progressive decline of all immune functions, but rather refers to a continuous remodeling process, whereby the adaptive immunity is preferentially affected compared with innate immunity. 20, 21 In this context, B-cell diversity decreases with age and is characterized by clonal expansions of B cells in vivo. EBV is a gamma-herpes virus that has a tropism for lymphocytes. The virus infects and replicates within epithelial cells and most viral particles are cleared by cytotoxic T cells. origin. This finding could be related to c-Rel (a subunit of NF-κB transcription factor) amplification, which has been observed exclusively in the GCB immunophenotype of DLBCL on the basis of gene expression profiling.
The oncogenic mechanisms of EBV are thought to be attributable predominantly to LMP1 LMP1 also deregulates the cell cycle. Everly et al showed that LMP1 increases expression of cyclin-dependent kinase 2 (Cdk2), phosphorylates retinoblastoma (Rb) protein, and inhibits expression of p27 Kip1 . 34 The p16 INK4a -Rb pathway has been shown to be hindered by LMP1.
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LMP1 also increases expression of Bcl-2 to prevent latently EBV-infected cells from 
Clinical features
EBV-positive DLBCL of the elderly is characterized by higher age distribution and an aggressive clinical course with a median survival of two years in Asian patients ( Figure 3A -B). 4, 7, 8, 10, 12, 13, 18 Initial reports emphasized that EBV-positive DLBCL of the elderly commonly involved extranodal sites. 2, 13 Site of primary extranodal involvement include the skin, soft tissue, bones, nasal cavity, pharynx/hypopharynx, tonsils, tongue, lung, pleura, stomach, liver, spleen, peritoneum, cecum and bone marrow. [4] [5] [6] [7] [8] 10, 39 Subsequently, several studies showed that lymph node involvement is very common, in up to 70% of patients. [4] [5] [6] [7] [8] 10, 39 EBV-positive DLBCLs, including EBV-positive DLBCL of the elderly, respond more poorly to treatment with a poorer outcome compared with patients who have EBV-negative DLBCL.
Therefore, novel therapeutic agents are needed to treat patients with EBV-positive DLBCL of the elderly. The concordance rate between EBER and LMP1 can reach 80% to 90%, but is not uniformly consistent.
The proportion of EBV-positive DLBCL cases among all DLBCL patients increases with age, 12, 44 which is analogous to the ABC subtype that also increases with age. 45 These findings are in accord with recent data indicating that aging is an important determinant of lymphoma biology. 46 In an effort to explain the proportional increase of ABC DLBCL with age, Mareschal et al 45 speculated that either a change in B-cell population during aging or on the putative pathological specificity of EBV-positive DLBCL of the elderly. Not surprisingly, most cases of EBV-positive DLBCL of the elderly displayed a striking shift to an ABC immunophenotype with prominent activation of NF-κB pathway. 8 
Differential Diagnosis
The major entities in the differential diagnosis of EBV-positive DLBCL of the elderly are summarized in Table 2 . In part, EBV-positive DLBCL of the elderly is a diagnosis of 
Genetic and miRNA profile
Only a few genetic studies on cases of EBV-positive DLBCL of the elderly have been performed. 8, 18 The immunoglobulin genes are monoclonally rearranged in most cases, with clonality of EBV also usually detectable using EBV terminal repeat regions probes and molecular techniques. 1, 5, 7, 8, 18, 47 IgH-mediated translocations are uncommon (~15%). 8, 18 However, these analyses were restricted to single loci (IGH, IGK, IGL, PAX5, C-MYC, BCL2
and BCL6). A single case with a t(9;14)(p13;q32) translocation involving the PAX5 gene has been reported. 48 Given the presence of a low number of genomic aberrations in EBV-positive DLBCL of the elderly, it has been suggested that immunosenescence coupled with the EBV oncogenic properties are sufficient and additional chromosomal alterations are therefore usually not needed for lymphomagenesis. 8 EBV was the first virus in which miRNAs were identified and 44 mature EBV-miRNAs are currently known. 49 A detailed list of EBV-miRNAs is summarized in Table 3 . EBV-miRNAs can regulate viral and cellular targets, and they generally target host transcripts during latent infection (Table 3) . 50 Several studies have shown that EBV-miRNAs contribute to EBV-induced oncogenesis.
EBV-miR-BART5 targets and degrades p53-up-regulated modulator of apoptosis, a proapoptotic protein. 55 EBV-miR-BHRF1 promotes B-cell transformation and proliferation and prevents apoptosis. 56 EBV-miR-BART9 and BART17-5p can downregulate BCL6 expression. 57 Considering the fact that BCL6 represses NF-κB, downregulation of BCL6 by EBV-miRNA might indirectly contribute to NF-κB activation. 57, 58 Riley et al 59 showed that numerous EBV-miR-Bam HI-A region rightward transcripts (BARTs) likely target at least 132 apoptotic mRNAs in latency type III infection, highlighting their collective influence on apoptosis regulation.
It also becomes evident that EBV-miRNAs have evolved to target multiple cellular pathways rather than a single pathway. Pathway analysis has predicted that there are several EBVmiRNA targeted genes in at least 20 specific pathways, including p53 feedback loops, B-cell activation, oxidative stress response, inflammation mediated by chemokines or the cytokine signaling pathway, the PI3K pathway and apoptosis ( Figure 6 ).
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Interestingly, cellular miRNAs are modulated by viral proteins. Mir-155 has been shown in DLBCL, especially in ABC subtype, and can be induced by LMP1 via the NF-κB pathway. 60 Of note, miR-155 has been shown to co-target INPP5D (SHIP1), a key target implicated in 63 Overexpression of miR-21 has been found to promote tumor progression and invasion in solid tumors via targeting PTEN. 64, 65 Mir-146a has ben shown to inhibit the NF-κB pathway in the NK/T-cell lymphoma cell lines. 66 Therefore, EBNA2 can provide extra signals via miRNAs to enhance the NF-κB and Akt pathways, thereby providing survival/proliferation benefits.
Novel therapeutic approaches
Novel therapeutic approaches need to be considered for patients with EBV-positive DLBCL of the elderly. Possible therapeutic approaches include: (1) EBV-specific adoptive immunotherapy; (2) microRNA-targeted therapy; (3) combination therapy based on EBV lytic phase induction followed by exposure of the tumor cells to anti-herpesvirus drugs; and (4) targeting specific signaling pathways, including the NF-κB pathway (Table 4 and Figure 6 ).
EBV-specific adoptive immunotherapy, in which EBV-specific cytotoxic T-lymphocytes (CTLs) are ex vivo activated and expanded and then reinfused seem promising. 67 Using this approach, EBV-specific CTLs could be engineered to recognize and lyse tumor cell targets via chimeric receptors, while maintaining their ability to proliferate in response to EBV target antigens and accordingly destroy virus-infected cells. 68 Optimal tumor eradication appears to require proper target antigen selection, co-stimulatory signalling and the ability of chimeric 
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Given that the EBV-positive DLBCL of the elderly is an aggressive post-germinal center Bcell neoplasm characterized by prominent NF-κB activation 8 , targeting the NF-κB pathway constitutes a rational therapeutic approach (Table 4) . Bortezomib, a proteasome inhibitor, has been found to induce apoptosis in EBV lymphoblastoid cell lines and to reduce canonical and non-canonical activities of NF-κB pathway. 75 A recent phase I/II clinical trial with bortezomib plus R-CHOP in DLBCL abrogated the adverse outcome in non-GCB and showed similar survival between GCB and non-GCB patients. 76 Bay 11-7085, a pharmacological inhibitor of NF-κB activity, or NF-κB/p65 small interfering RNA (siRNA), can inhibit DLBCL growth in vitro via induction of apoptosis. 25 In contrast with bortezomib, the latter strategies of NF-κB inhibition down-regulate expression of key NF-κB regulated gene products, including Bcl-2
and Bcl-XL. 25,75 NF-κB essential modulator-binding domain peptide has been shown to inhibit NF-κB target gene expression and reduce tumor burden in an in vivo model as well. 77 Recent evidence indicates a critical function of PI3K-PDK1 signaling upstream of NF-κB in ABC-DLBCL cells. 78 PI3K inhibition reduced NF-κB activity and decreased the expression of NF-κB target genes in ABC-DLBCL cell lines, providing a rationale for the pharmacological use of PI3K inhibitors for treating patients with ABC-type DLBCL. 78 In addition, LMP1 has been implicated in the activation of the PI3K/Akt signaling pathway, which lies upstream of mTOR. 79 Experimental evidence stemming either from dual PI3K/mTOR inhibitors or a single mTOR inhibitor further reinforces the putative exploitation of LMP1/LMP2A-activated PI3K/Akt/mTOR signaling pathway. 80 Another attractive target for developing antiviral or antitumor strategies is EBNA1 owing to its essential role in maintaining the EBV genome and the consistent expression of EBNA1 in all proliferating EBV-positive cells. 81 
Sun et al showed that Hsp90 inhibitors block the outgrowth of EBV-infected malignant cells in vitro and in vivo
through an EBNA1-dependent mechanism. 81 Notably, Hsp90 inhibitors have been found to 
Conclusions
We have provided a comprehensive review of EBV-positive DLBCL of the elderly discussing its epidemiologic, pathogenetic and clinicopathologic features, differential diagnosis, and
proposed some comments about potential novel therapeutic approaches for patients with this disease. Currently, an arbitrary cutoff of 50 years is used to define this entity in the current WHO classification, but patients younger than 50 years can also be affected. Although these tumors were originally reported as usually being extranodal, it is clear that nodal presentation 
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